Physically crosslinked injectable hydrogels for long-term delivery of oncolytic adenoviruses for cancer treatment

2019 ◽  
Vol 7 (10) ◽  
pp. 4195-4207 ◽  
Author(s):  
Thai Minh Duy Le ◽  
Bo-Kyeong Jung ◽  
Yi Li ◽  
Huu Thuy Trang Duong ◽  
Thanh Loc Nguyen ◽  
...  
Keyword(s):  
Cancer Treatment ◽  
Injectable Hydrogels ◽  
Injectable Hydrogel ◽  
Temperature Responsive ◽  
Oncolytic Adenoviruses ◽  
Term Delivery ◽  
Physically Crosslinked ◽  
Hydrogel System

A dual pH- and temperature-responsive physically crosslinked and injectable hydrogel system was developed for efficient and long-term delivery of oncolytic adenoviruses (Ads).

Strong underwater adhesion of injectable hydrogels triggered by diffusion of small molecules

2021 ◽  
Author(s):  
Xing Su ◽  
Wenyue Xie ◽  
Pudi Wang ◽  
Zhuoling Tian ◽  
Hao Wang ◽  
...  
Keyword(s):  
Small Molecules ◽  
Tea Polyphenols ◽  
Injectable Hydrogels ◽  
Injectable Hydrogel ◽  
Underwater Adhesion ◽  
Physically Crosslinked

It is challenging for injectable hydrogels to achieve high underwater adhesiveness. Based on this concern, we report a fully physically crosslinked injectable hydrogel composed of gelatin, tea polyphenols and urea,...

Fabrication of an injectable hydrogel with inherent photothermal effects from tannic acid for synergistic photothermal-chemotherapy

2021 ◽  
Author(s):  
Xiao Zhu ◽  
Binggang Guan ◽  
Ziling Sun ◽  
Xin Tian ◽  
Xinming Li
Keyword(s):  
Cancer Treatment ◽  
Tannic Acid ◽  
Near Infrared ◽  
Shear Thinning ◽  
Injectable Hydrogels ◽  
Injectable Hydrogel ◽  
Promising Strategy ◽  
Photothermal Effects

Developing injectable hydrogels with near-infrared (NIR)-responsive photothermal effects has increasingly become a promising strategy for local cancer treatment via combinational photothermal-chemotherapy. Herein, a biocompatible hydrogel with a remarkable shear-thinning and...

Long-term effects of childhood cancer treatment on hormonal and ultrasound markers of ovarian reserve

2019 ◽  
Author(s):  
van den Berg MH ◽  
Overbeek A ◽  
Lambalk CB ◽  
Kaspers GJL ◽  
Bresters D ◽  
...  
Keyword(s):  
Cancer Treatment ◽  
Childhood Cancer ◽  
Ovarian Reserve ◽  
Long Term Effects

scholarly journals The impact of lymphedema on health-related quality of life up to 10 years after breast cancer treatment

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Mads G. Jørgensen ◽  
Navid M. Toyserkani ◽  
Frederik G. Hansen ◽  
Anette Bygum ◽  
Jens A. Sørensen
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Cancer Treatment ◽  
Breast Cancer Treatment ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related ◽  
The Impact

AbstractThe impact of breast cancer-related lymphedema (BCRL) on long-term quality of life is unknown. The aim of this study was to investigate the impact of BCRL on health-related quality of life (HRQoL) up to 10 years after breast cancer treatment. This regional population-based study enrolled patients treated for breast cancer with axillary lymph node dissection between January 1st 2007 and December 31th 2017. Follow up and assessments of the included patients were conducted between January 2019 and May 2020. The study outcome was HRQoL, evaluated with the Lymphedema Functioning, Disability and Health Questionnaire, the Disabilities of the Arm, Shoulder and Hand Questionnaire and the Short Form (36) Health Survey Questionnaire. Multivariate linear logistic regression models adjusted for confounders provided mean score differences (MDs) with 95% confidence intervals in each HRQoL scale and item. This study enrolled 244 patients with BCRL and 823 patients without BCRL. Patients with BCRL had significantly poorer HRQoL than patients without BCRL in 16 out of 18 HRQoL subscales, for example, in physical function (MDs 27, 95%CI: 24; 30), mental health (MDs 24, 95%CI: 21; 27) and social role functioning (MDs 20, 95%CI: 17; 23). Age, BMI, BCRL severity, hand and dominant arm affection had only minor impact on HRQoL (MDs < 5), suggesting a high degree of inter-individual variation in coping with lymphedema. This study showed that BCRL is associated with long-term impairments in HRQoL, especially affecting the physical and psychosocial domains. Surprisingly, BCRL diagnosis rather than clinical severity drove the largest impairments in HRQoL.

scholarly journals Injectable polymeric nanoparticle hydrogel system for long-term anti-inflammatory effect to treat osteoarthritis

2021 ◽  
Author(s):  
Bo-Bae Seo ◽  
Youngjoong Kwon ◽  
Jun Kim ◽  
Ki Hyun Hong ◽  
Sung-Eun Kim ◽  
...  
Keyword(s):  
Polymeric Nanoparticle ◽  
Anti Inflammatory ◽  
Hydrogel System ◽  
Inflammatory Effect

A catechol-chitosan-based adhesive and injectable hydrogel resistant to oxidation and compatible with cell therapy

2021 ◽  
Author(s):  
Capucine Guyot ◽  
Atma Adoungotchodo ◽  
Werner Taillades ◽  
Marta Cerruti ◽  
Sophie Lerouge
Keyword(s):  
Cell Therapy ◽  
Injectable Hydrogels ◽  
Injectable Hydrogel ◽  
Encapsulated Cells

Injectable hydrogels designed for cell therapy need to be adhesive to the surrounding tissues to maximize their retention and the communication between the host and the encapsulated cells. Catechol grafting...

scholarly journals Cancer Treatment–Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy

2021 ◽  
Vol 22 (5) ◽  
Author(s):  
Anna Diana ◽  
Francesca Carlino ◽  
Emilio Francesco Giunta ◽  
Elisena Franzese ◽  
Luigi Pio Guerrera ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Loss ◽  
Cancer Treatment ◽  
Endocrine Therapy ◽  
Aromatase Inhibitors ◽  
Bone Health ◽  
Optimal Time ◽  
Breast Cancer Patients ◽  
Antiresorptive Agents

Opinion statementAbout 70–80% of early breast cancer (BC) patients receive adjuvant endocrine therapy (ET) for at least 5 years. ET includes in the majority of cases the use of aromatase inhibitors, as upfront or switch strategy, that lead to impaired bone health. Given the high incidence and also the high prevalence of BC, cancer treatment–induced bone loss (CTIBL) represents the most common long-term adverse event experimented by patients with hormone receptor positive tumours. CTIBL is responsible for osteoporosis occurrence and, as a consequence, fragility fractures that may negatively affect quality of life and survival expectancy. As recommended by main international guidelines, BC women on aromatase inhibitors should be carefully assessed for their fracture risk at baseline and periodically reassessed during adjuvant ET in order to early detect significant worsening in terms of bone health. Antiresorptive agents, together with adequate intake of calcium and vitamin D, should be administered in BC patients during all course of ET, especially in those at high risk of osteoporotic fractures, as calculated by tools available for clinicians. Bisphosphonates, such as zoledronate or pamidronate, and anti-RANKL antibody, denosumab, are the two classes of antiresorptive drugs used in clinical practice with similar efficacy in preventing bone loss induced by aromatase inhibitor therapy. The choice between them, in the absence of direct comparison, should be based on patients’ preference and compliance; the different safety profile is mainly related to the route of administration, although both types of drugs are manageable with due care, since most of the adverse events are predictable and preventable. Despite advances in management of CTIBL, several issues such as the optimal time of starting antiresorptive agents and the duration of treatment remain unanswered. Future clinical trials as well as increased awareness of bone health are needed to improve prevention, assessment and treatment of CTIBL in these long-term survivor patients.

Innovatory role of nanomaterials as bio-tools for treatment of cancer

2020 ◽  
Vol 0 (0) ◽  
Author(s):  
Khuram Shahzad Ahmad ◽  
Muntaha Talat ◽  
Shaan Bibi Jaffri ◽  
Neelofer Shaheen
Keyword(s):  
Cancer Treatment ◽  
Cancer Therapeutics ◽  
Physicochemical Characteristics ◽  
Global Scale ◽  
Current Review ◽  
Anti Cancer ◽  
Different Types ◽  
Cancerous Cells

AbstractConventional treatment modes like chemotherapy, thermal and radiations aimed at cancerous cells eradication are marked by destruction pointing the employment of nanomaterials as sustainable and auspicious materials for saving human lives. Cancer has been deemed as the second leading cause of death on a global scale. Nanomaterials employment in cancer treatment is based on the utilization of their inherent physicochemical characteristics in addition to their modification for using as nano-carriers and nano-vehicles eluted with anti-cancer drugs. Current work has reviewed the significant role of different types of nanomaterials in cancer therapeutics and diagnostics in a systematic way. Compilation of review has been done by analyzing voluminous investigations employing ERIC, MEDLINE, NHS Evidence and Web of Science databases. Search engines used were Google scholar, Jstore and PubMed. Current review is suggestive of the remarkable performance of nanomaterials making them candidates for cancer treatment for substitution of destructive treatment modes through investigation of their physicochemical characteristics, utilization outputs and long term impacts in patients.

scholarly journals How long is long-term? Delivery of anti-HIV antibodies using AAV vector

2019 ◽  
Vol 5 ◽  
pp. 49
Author(s):  
J. Martinez-Navio ◽  
R. Desrosiers ◽  
S. Fuchs ◽  
D. Mendes ◽  
E. Rakasz ◽  
...  
Keyword(s):  
Aav Vector ◽  
Term Delivery ◽  
Hiv Antibodies ◽  
Anti Hiv

scholarly journals Effects of bicarbonate/lactate-buffered neutral peritoneal dialysis fluids on angiogenesis-related proteins in patients undergoing peritoneal dialysis

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Hiromichi Ueno ◽  
Tetsu Miyamoto ◽  
Hiroyuki Morimoto ◽  
Kenya Sanada ◽  
Ikutaro Furuno ◽  
...  
Keyword(s):  
Peritoneal Dialysis ◽  
Antibody Array ◽  
The Novel ◽  
Term Delivery ◽  
Cxc Chemokine ◽  
Related Proteins ◽  
Chemokine Family ◽  
Dialysis Fluids

Abstract Background In order to facilitate the safe and long-term delivery of peritoneal dialysis (PD), it is necessary to improve the biocompatibility of peritoneal dialysis fluids (PDFs). The novel bicarbonate/lactate-buffered neutral PDFs (B/L-PDFs) are expected to be improved biocompatible. This study evaluated the biocompatibility of B/L-PDFs by analysis on the profile of angiogenesis-related proteins in drained dialysate of patients undergoing PD. Methods Concentrations of 20 angiogenesis-related proteins in the dialysate were semi-quantitatively determined using a RayBio® Human Angiogenesis Antibody Array and were compared between B/L-PDFs and conventional lactate-buffered neutral PDFs (L-PDFs). Results The expression of growth-related oncogene (GRO α/β/γ), which belongs to the CXC chemokine family, decreased significantly after use of the B/L-PDFs compared to the L-PDFs (P = 0.03). The number of the proteins with lower level in the B/L-PDFs compared with L-PDFs was significantly negatively correlated with the PD duration (Spearman ρ = − 0.81, P = 0.004). Conclusion This study suggested that B/L-PDFs are more biocompatible than conventional PDFs.

Sign in / Sign up

Export Citation Format

Share Document